Evidence map›Paper›PMID 38770190›Full record

ReviewEndocrine oncology (Bristol, England)2024

How to design a theranostic trial?

Dheeratama Siripongsatian, Quido G de Lussanet de la Sablonière, Frederik Anton Verburg, Tessa Brabander

Abstract readReview
In one paragraph

Review in Endocrine oncology (Bristol, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dheeratama SiripongsatianNational Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, Thailand.
Quido G de Lussanet de la SablonièreDepartment of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands.
Frederik Anton VerburgDepartment of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands.
Tessa BrabanderDepartment of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands.ORCID 0000-0002-8000-6490

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The field of nuclear theranostic clinical trials is continuously expanding as an increasing number of novel agents and treatment combinations are explored for treating advanced and metastatic cancers. Moving from 'bench-to-bedside' is oftentimes a complex and lengthy process. The objective of this overview is to explore the basic elements involved in designing clinical trials with a special focus on theranostics in nuclear medicine. The 'bench-to-bedside' journey involves translating basic scientific research into patient-effective treatments. Preclinical studies, a crucial initial step, are a complex process encompassing

Indexed as

clinical trialsnuclear medicineradionuclide therapytheranostics

Identifiers

PMID38770190
PMCPMC11103757

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.